The latest news on cancer diagnostics, liquid biopsy, and cancer risk testing.
The company reported $112.4 million in revenues compared to $83.2 million in Q4 2019, beating the average Wall Street estimate of $106.6 million.
The firm posted total software-related revenues of $18.6 million, up 1 percent from $18.4 million in Q4 2019.
The firm expects to release an expanded liquid biopsy panel this year to help pharmaceutical partners perform blood-based biomarker discovery work.
Oncocyte is now the sole shareholder of Razor, which developed the DetermaRx test that has now become the firm's flagship clinical offering.
For the 12 months ended Dec. 31, 2020, Biocartis' revenues rose to €43.1 million ($52.7 million) from €37.4 million in 2019.
